Analyst Price Targets — GRAL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 12:35 pm | Kallum Titchmarsh | Morgan Stanley | $60.00 | $43.03 | TheFly | Grail price target lowered to $60 from $110 at Morgan Stanley |
| February 20, 2026 11:59 am | Catherine Ramsey Schulte | Robert W. Baird | $82.00 | $101.53 | TheFly | Grail price target lowered to $82 from $113 at Baird |
| February 20, 2026 11:49 am | — | Canaccord Genuity | $80.00 | $101.53 | TheFly | Grail price target lowered to $80 from $105 at Canaccord |
| February 17, 2026 10:11 am | — | Robert W. Baird | $113.00 | $97.50 | TheFly | Grail initiated with an Outperform at Baird |
| January 26, 2026 2:35 pm | — | Guggenheim | $130.00 | $107.58 | TheFly | Grail price target raised to $130 from $100 at Guggenheim |
| December 1, 2025 9:28 pm | — | Morgan Stanley | $110.00 | $98.27 | TheFly | Grail assumed with an Equal Weight at Morgan Stanley |
| November 12, 2025 11:13 am | Subbu Nambi | Guggenheim | $100.00 | $83.39 | StreetInsider | Guggenheim Upgrades GRAIL, Inc. (GRAL) to Buy |
| October 22, 2025 10:34 am | Kyle Mikson | Canaccord Genuity | $85.00 | $78.28 | TheFly | Grail price target raised to $85 from $75 at Canaccord |
| October 3, 2025 11:59 am | — | UBS | $75.00 | $64.73 | TheFly | Grail price target raised to $75 from $43 at Canaccord |
| April 21, 2025 10:50 am | — | Canaccord Genuity | $32.00 | $26.42 | TheFly | Canaccord starts Grail with a Buy, sees 'solid upside' |
Latest News for GRAL
MENLO PARK, Calif., March 2, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 19,500 shares of GRAIL's common stock to 20 recently hired non-executive employees as an inducement material to their acceptance of…
New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "updating our cash-burn guidance further to no more than $290 million for the…
MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, Mar. 3 at 10:30 a.m.
New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "updating our cash-burn guidance further to no more than $290 million for…
Follow-up data could make the trial's findings look much better than they do now. Management believes the results of the trial won't impact an approval decision by the Food and Drug Administration (FDA) We're bullish on these 10 stocks ›
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GRAL.
U.S. House Trading
No House trades found for GRAL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.